Primary Outcome Measures:
- Impact of current procedures for diagnosis, management, and follow-up on disease status
- Natural history of patients with chronic myelogenous leukemia who achieve response to imatinib mesylate
- Health perceptions, symptoms, insurance issues, and work issues
- Affect of medication compliance and planned dose reduction on imatinib mesylate effectiveness
- Molecular and biologic factors associated with disease progression and good and poor response to imatinib mesylate
OBJECTIVES:
- Determine the impact of current procedures for diagnosis, management, and follow-up on disease status of patients with newly diagnosed chronic myelogenous leukemia (CML).
- Determine the natural history of patients with CML who achieve response to imatinib mesylate.
- Determine the health perceptions, symptoms, insurance issues, and work issues of these patients.
- Determine whether medication compliance and planned dose reduction affect imatinib mesylate effectiveness in these patients.
- Determine the molecular and biologic factors associated with disease progression and good and poor response to imatinib mesylate in these patients.
OUTLINE: This is a longitudinal, prospective, cohort study.
Patients complete quality of life, functional status, medical and treatment history, and medication questionnaires at baseline and then every 6 months for 5 years.
Blood samples are collected at baseline and then every 6 months for 5 years. Specimens may be examined in the future in gene array studies and mutation analyses.
PROJECTED ACCRUAL: A total of 2,000 patients will be accrued for this study within 2 years.
Purpose
